


TOZET-29/ET600

FIGURE 1









FIGURE 2

3/22

FIGURE 3



(-) Betaxolol




(+) Betaxolol

FOOT-294EFOO

FIGURE 4





5/22

FIGURE 5

10/21/00 10/21/00

FIGURE 6a



7/22





FIGURE 6b


8/22

FIGURE 7a




9/22

FIGURE 7b




10/22

FIGURE 7c



11/22

FIGURE 8a




Figure 9






FIGURE 10A


14/22




(q)



(p)



(b)



(c)

SUBSTITUTE SHEET (RULE 26)

FIGURE 10B

09/913762-112701

15/22




FIGURE 10c

16/22




FIGURE 11

17/22




FIGURE 12

18/22







FIGURE 13

19/22


FIGURE 14




(-) Antagonist




(+) Antagonist

Upregulation monitored by increased
luciferase activity in cells

20/22




Paramete	Value	SE	Lower CL	Upper CL	Paramete	Value	SE	Lower CL	Upper CL
a (Iso ave)	107.98	4.99006	96.4729	119.4871	a (ave bet)	91.99781	4.066952	82.6194	101.3762
c (Iso ave)	3.04E-06	8.74E-07	1.57E-06	5.9E-06	c (ave bet)	1.16E-07	2.64E-08	6.85E-08	1.96E-07
d (Iso ave)	263.6671	9.532958	241.684	285.6501	d (ave bet)	194.6117	3.153874	187.3389	201.8846
b (Iso ave)	1	0	1	1	b (ave bet)	1	0	1	1



Paramete	Value	SE	Lower CL	Upper CL
a (ave sot)	91.61328	3.703476	83.07304	100.1535
c (ave sot)	1.59E-06	4.07E-07	8.77E-07	2.87E-06
d (ave sot)	208.4677	5.759934	195.1852	221.7501
b (ave sot)	1	0	1	1

FIGURE 15

A



B





FIGURE 16

22/22




FIGURE 17